282 related articles for article (PubMed ID: 35135481)
1. Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE.
Fishbane S; Ford M; Fukagawa M; McCafferty K; Rastogi A; Spinowitz B; Staroselskiy K; Vishnevskiy K; Lisovskaja V; Al-Shurbaji A; Guzman N; Bhandari S
BMC Nephrol; 2022 Feb; 23(1):59. PubMed ID: 35135481
[TBL] [Abstract][Full Text] [Related]
2. DIALIZE China: A Phase IIIb, Randomized, Placebo-Controlled Study to Reduce Predialysis Hyperkalemia With Sodium Zirconium Cyclosilicate in Chinese Patients.
Ni Z; Lu R; Xu X; Bian X; Zhou Z; Yang J; Luo Q; Chen M; Chen C; Sun X; Yu L; He Q; Jiang H; Yuan W; Li Y; Zhou R; Wang J; Zhang X; Zuo L; Meng X; Chang Z; Zhao J; Wessman P; Xiang P;
Clin Ther; 2023 Jul; 45(7):633-642. PubMed ID: 37385905
[TBL] [Abstract][Full Text] [Related]
3. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.
Fishbane S; Ford M; Fukagawa M; McCafferty K; Rastogi A; Spinowitz B; Staroselskiy K; Vishnevskiy K; Lisovskaja V; Al-Shurbaji A; Guzman N; Bhandari S
J Am Soc Nephrol; 2019 Sep; 30(9):1723-1733. PubMed ID: 31201218
[TBL] [Abstract][Full Text] [Related]
4. Emergency Potassium Normalization Treatment Including Sodium Zirconium Cyclosilicate: A Phase II, Randomized, Double-blind, Placebo-controlled Study (ENERGIZE).
Peacock WF; Rafique Z; Vishnevskiy K; Michelson E; Vishneva E; Zvereva T; Nahra R; Li D; Miller J
Acad Emerg Med; 2020 Jun; 27(6):475-486. PubMed ID: 32149451
[TBL] [Abstract][Full Text] [Related]
5. Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis.
Zhang Y; Xu R; Wang F; Liu Y; Xu J; Zhao N; Cheng F; Long L; Jia J; Lin S
Cardiovasc Drugs Ther; 2021 Oct; 35(5):1057-1066. PubMed ID: 33459923
[TBL] [Abstract][Full Text] [Related]
6. Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose-response, phase 2/3 study.
Kashihara N; Nishio T; Osonoi T; Saka Y; Imasawa T; Ohtake T; Mizuno H; Shibagaki Y; Kim H; Yajima T; Sarai N
Clin Exp Nephrol; 2020 Dec; 24(12):1144-1153. PubMed ID: 32779057
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the effect of sodium zirconium cyclosilicate on arrhythmia-related cardiovascular outcomes in patients receiving chronic haemodialysis with hyperkalaemia: protocol for the multicentre, randomised, controlled DIALIZE-Outcomes study.
Fishbane S; Jadoul M; Dember L; Kovesdy CP; Al-Shurbaji A; Lisovskaja V; Sekar P; Katona B; Guzman N; Herzog C
BMJ Open; 2023 May; 13(5):e071309. PubMed ID: 37230521
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study.
Roger SD; Lavin PT; Lerma EV; McCullough PA; Butler J; Spinowitz BS; von Haehling S; Kosiborod M; Zhao J; Fishbane S; Packham DK
Nephrol Dial Transplant; 2021 Jan; 36(1):137-150. PubMed ID: 32030422
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of sodium zirconium cyclosilicate in patients with baseline serum potassium level ≥ 5.5 mmol/L: pooled analysis from two phase 3 trials.
Amin AN; Menoyo J; Singh B; Kim CS
BMC Nephrol; 2019 Dec; 20(1):440. PubMed ID: 31791288
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE.
Roger SD; Spinowitz BS; Lerma EV; Singh B; Packham DK; Al-Shurbaji A; Kosiborod M
Am J Nephrol; 2019; 50(6):473-480. PubMed ID: 31658466
[TBL] [Abstract][Full Text] [Related]
11. Course of Hyperkalemia in Patients on Hemodialysis.
Spinowitz B; Fishbane S; Fukagawa M; Ford M; Guzman N; Rastogi A
Int J Nephrol; 2022; 2022():6304571. PubMed ID: 35531468
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacodynamic Dose-Response Analysis of Serum Potassium Following Dosing with Sodium Zirconium Cyclosilicate.
Penland RC; Åstrand M; Boulton DW; Någård M
Clin Pharmacokinet; 2024 Apr; 63(4):551-560. PubMed ID: 38504082
[TBL] [Abstract][Full Text] [Related]
13. Sodium zirconium cyclosilicate increases serum bicarbonate concentrations among patients with hyperkalaemia: exploratory analyses from three randomized, multi-dose, placebo-controlled trials.
Roger SD; Spinowitz BS; Lerma EV; Fishbane S; Ash SR; Martins JG; Quinn CM; Packham DK
Nephrol Dial Transplant; 2021 Apr; 36(5):871-883. PubMed ID: 32588050
[TBL] [Abstract][Full Text] [Related]
14. Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.
Spinowitz BS; Fishbane S; Pergola PE; Roger SD; Lerma EV; Butler J; von Haehling S; Adler SH; Zhao J; Singh B; Lavin PT; McCullough PA; Kosiborod M; Packham DK;
Clin J Am Soc Nephrol; 2019 Jun; 14(6):798-809. PubMed ID: 31110051
[TBL] [Abstract][Full Text] [Related]
15. Effect of Sodium Zirconium Cyclosilicate on Serum Potassium and Bicarbonate in Patients with Hyperkalemia and Metabolic Acidosis Associated with Chronic Kidney Disease: Rationale and Design of the NEUTRALIZE Study.
Ash SR; Batlle D; Kendrick J; Oluwatosin Y; Pottorf W; Brahmbhatt Y; Guerrieri E; Fried L
Nephron; 2022; 146(6):599-609. PubMed ID: 35462371
[TBL] [Abstract][Full Text] [Related]
16. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.
Takkar C; Nassar T; Qunibi W
Expert Opin Pharmacother; 2021 Jan; 22(1):19-28. PubMed ID: 32892634
[TBL] [Abstract][Full Text] [Related]
17. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.
Kosiborod M; Rasmussen HS; Lavin P; Qunibi WY; Spinowitz B; Packham D; Roger SD; Yang A; Lerma E; Singh B
JAMA; 2014 Dec; 312(21):2223-33. PubMed ID: 25402495
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of sodium zirconium cyclosilicate for the management of acute and chronic hyperkalemia in children with chronic kidney disease 4-5 and on dialysis.
Khandelwal P; Shah S; McAlister L; Cleghorn S; King L; Shroff R
Pediatr Nephrol; 2024 Apr; 39(4):1213-1219. PubMed ID: 37857905
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study.
Zannad F; Hsu BG; Maeda Y; Shin SK; Vishneva EM; Rensfeldt M; Eklund S; Zhao J
ESC Heart Fail; 2020 Feb; 7(1):54-64. PubMed ID: 31944628
[TBL] [Abstract][Full Text] [Related]
20. Use of Renin-Angiotensin System Blockers Increases Serum Potassium in Anuric Hemodialysis Patients.
Movilli E; Camerini C; Gaggia P; Zubani R; Cancarini G
Am J Nephrol; 2018; 48(2):79-86. PubMed ID: 30071530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
